Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IMCC
IMCC logo

IMCC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.425
Open
0.392
VWAP
0.37
Vol
7.69M
Mkt Cap
3.02M
Low
0.313
Amount
2.83M
EV/EBITDA(TTM)
51.74
Total Shares
5.89M
EV
12.09M
EV/OCF(TTM)
8.38
P/S(TTM)
0.05
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
Show More

Events Timeline

(ET)
2026-03-17
09:00:00
Avant Brands Terminates Trademark Licensing Agreement with Adjupharm
select
2026-03-17
08:50:00
IM Cannabis Signs LOI to Acquire 51% of Blackaxe
select
2026-02-05 (ET)
2026-02-05
16:50:00
IM Cannabis Files to Sell 9.79M Common Shares
select
2026-01-05 (ET)
2026-01-05
09:10:00
IM Cannabis Appoints Alon Dayan to Board of Directors
select
2025-12-30 (ET)
2025-12-30
07:50:00
IM Cannabis Actively Evaluating Expansion Opportunities in U.S. Market
select
2025-12-12 (ET)
2025-12-12
16:10:00
IM Cannabis Appoints Asi Levi as CFO
select
2025-10-29 (ET)
2025-10-29
16:40:12
IM Cannabis CFO Uri Birenberg Resigns for Personal Reasons
select
2025-10-23 (ET)
2025-10-23
09:14:59
IM Cannabis to purchase a 60% interest in quantum computing firm for as much as $54 million
select
2025-09-05 (ET)
2025-09-05
07:10:23
IM Cannabis Restores Compliance with Nasdaq Requirements
select
2025-07-09 (ET)
2025-07-09
08:08:44
IM Cannabis appoints Adler to board of directors
select

News

seekingalpha
9.5
14:11 PMseekingalpha
PinnedIM Cannabis Reports FY Revenue of C$54.7M
  • Annual Revenue Performance: IM Cannabis reported a fiscal year revenue of C$54.7 million, demonstrating resilience in the face of market challenges, which reflects the company's potential for growth despite adversity.
  • Gross Profit Increase: The company's gross profit rose approximately 15% year-over-year to C$9.686 million, primarily driven by enhanced cost efficiencies and optimized supply chains, laying a solid foundation for future profitability.
  • Market Performance Volatility: Despite the improved financial metrics, IMCC shares fell by 6.8%, indicating market concerns regarding the company's future growth, which could impact investor confidence.
  • Contribution from German Market: The higher-margin sales in Germany significantly boosted overall performance, indicating that the company's international expansion strategy is gradually yielding results, with potential for further diversification of revenue streams in the future.
seekingalpha
8.5
03-17seekingalpha
IM Cannabis to Acquire 51% of Blackaxe Technologies
  • Strategic Expansion Opportunity: IM Cannabis (IMCC) has signed a letter of intent to acquire 51% of Polish company Blackaxe Technologies, marking a potential entry into the defense and homeland security technology sectors, thereby enhancing its market competitiveness.
  • Integration of Technical Expertise: Blackaxe specializes in advanced defense and intelligence solutions, and the acquisition will help IMCC integrate this technical expertise, thereby improving its capabilities and product offerings in related industries.
  • Positive Market Reaction: Following the acquisition announcement, IMCC's stock rose 13.16% in premarket trading to $0.8955 per share, indicating investor optimism regarding the transaction.
  • Future Growth Potential: By entering the defense and security technology market, IMCC not only diversifies its business model but also capitalizes on the growth potential in this sector, further driving its long-term strategic development.
PRnewswire
8.5
03-17PRnewswire
IM Cannabis to Acquire 51% Stake in Blackaxe Technologies
  • Strategic Expansion: IM Cannabis Corp. has announced a non-binding letter of intent to acquire 51% of Blackaxe Technologies, marking a strategic move into the defense and security technology sectors, which is expected to enhance its market competitiveness.
  • Growing Market Demand: The global defense and security market is rapidly expanding due to rising geopolitical tensions, and IMC's acquisition will enable it to leverage Blackaxe's advanced capabilities in satellite intelligence and counter-drone technologies to meet increasing market demands.
  • Technological Integration Advantage: Blackaxe specializes in defense solutions based on advanced Israeli technologies, and IMC's acquisition will allow it to integrate these technologies, enhancing its business diversification and innovation capabilities beyond the medical cannabis sector.
  • Transaction Conditions and Risks: The deal is subject to due diligence and regulatory approvals, and IMC faces multiple risks including industry regulations and market competition; successfully completing the transaction will have significant implications for its future growth.
Newsfilter
8.5
03-17Newsfilter
IM Cannabis Corp Plans to Acquire 51% of Blackaxe Technologies
  • Strategic Expansion Plan: IM Cannabis Corp has announced a non-binding letter of intent to acquire 51% of Polish technology company Blackaxe, marking a strategic expansion into the defense and security technology sectors, aiming to leverage the growth potential of the global defense market.
  • Surging Market Demand: The global defense market is rapidly expanding due to rising geopolitical tensions and the emergence of new threats, particularly the increasing demand for low-cost drones and advanced missile systems, and IMC's acquisition plan is designed to address this market need.
  • Integration of Technological Advantages: Blackaxe specializes in satellite intelligence, imagery and AI analytics, and counter-drone solutions, utilizing advanced Israeli technologies to support governments and security agencies in addressing evolving aerial and intelligence threats, and IMC's acquisition will enhance its technological capabilities.
  • Transaction Conditions and Risks: The proposed transaction is subject to due diligence, execution of definitive agreements, and regulatory approvals, with IMC facing industry regulations, market competition, and other uncertainties, indicating that the successful completion of the transaction remains at risk.
PRnewswire
8.5
01-26PRnewswire
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
  • Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through a third-party loan agreement to address liquidity needs, enhancing financial flexibility amid operational challenges.
  • First Note Details: The first note issued amounts to $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and has an 18-month maturity, reflecting the company's focus on effective debt management.
  • Second Note Arrangement: The second note totals $632,911 with similar terms, including an 8% interest rate and identical repayment structure, further solidifying the company's financial foundation.
  • Equity Conversion Rights: Both notes are convertible into common shares at a price of $1.47 or 90% of the lowest VWAP over 20 days, providing the company with a potential equity financing avenue.
Newsfilter
8.5
01-26Newsfilter
IM Cannabis Corp. Secures $2.17 Million in Debt Financing
  • Financing Amount: IM Cannabis Corp. successfully raised $2.17 million through an agreement with a third-party lender to address liquidity needs, thereby enhancing financial flexibility.
  • First Note Details: The company issued a first note of $1.54 million with an 8% annual interest rate, increasing to 14% upon default, and an 18-month maturity, reflecting a cautious approach to debt management.
  • Second Note Issuance: The second note amounts to $632,911.50 with the same interest rate and maturity as the first, further solidifying the company's financial foundation to support operations and strategic initiatives.
  • Equity Conversion Rights: Both notes are convertible into common shares, with the first note's conversion price set at $1.47 per share, ensuring the company maintains flexibility in future financing while providing potential value appreciation for investors.

Valuation Metrics

The current forward P/E ratio for IM Cannabis Corp (IMCC.O) is -4.45, compared to its 5-year average forward P/E of -109.22. For a more detailed relative valuation and DCF analysis to assess IM Cannabis Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-109.22
Current PE
-4.45
Overvalued PE
300.02
Undervalued PE
-518.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.31
Current EV/EBITDA
8.33
Overvalued EV/EBITDA
25.32
Undervalued EV/EBITDA
-31.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.92
Current PS
0.14
Overvalued PS
2.28
Undervalued PS
-0.43

Financials

AI Analysis
Annual
Quarterly

Whales Holding IMCC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is IM Cannabis Corp (IMCC) stock price today?

The current price of IMCC is 0.365 USD — it has decreased -10.54

What is IM Cannabis Corp (IMCC)'s business?

IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.

What is the price predicton of IMCC Stock?

Wall Street analysts forecast IMCC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMCC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IM Cannabis Corp (IMCC)'s revenue for the last quarter?

IM Cannabis Corp revenue for the last quarter amounts to 13.85M USD, decreased -0.23

What is IM Cannabis Corp (IMCC)'s earnings per share (EPS) for the last quarter?

IM Cannabis Corp. EPS for the last quarter amounts to -0.75 USD, increased 82.93

How many employees does IM Cannabis Corp (IMCC). have?

IM Cannabis Corp (IMCC) has 55 emplpoyees as of March 31 2026.

What is IM Cannabis Corp (IMCC) market cap?

Today IMCC has the market capitalization of 3.02M USD.